KVAC signs non-binding LOI to merge with Boston clinical-stage biopharma company

Keen Vision Acquisition Corp.

On March 22, 2024, KVAC entered a non-binding LOI for a potential business combination with a clinical-stage biopharma target.
Target is based in Boston, U.S., focusing on stem cell bioengineering platform and next-gen cell/gene therapies.
Target's several experimental gene therapies have FDA IND approvals and ongoing trials at multiple U.S. hospitals.
LOI is non-binding and no definitive agreement has been executed; KVAC has until October 27, 2024 to close a business combination.
Automatic six-month extension period available to KVAC upon execution of the LOI.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.